Skip to main content
. Author manuscript; available in PMC: 2018 Dec 15.
Published in final edited form as: Cancer Res. 2017 Oct 20;77(24):6914–6926. doi: 10.1158/0008-5472.CAN-17-2105

Figure 7.

Figure 7

Combined targeting of AKT and SGK completely inhibits proliferation of PI3K-active cancer cells. A-B dose-response plots showing the effect of SGK1 depletion on the efficacy of PI3K targeting. Dox+ values are shown as ratio to completely untreated cells in A, and as ratio to doxycycline-treated, GDC-0941-untreated cells in B. C, Western blot analysis of the phosphorylation of AKT and S6 in the THJ16T and T4888M cells upon 6 hours treatment with the indicated inhibitors at concentrations corresponding to EC75-EC90 as single drug. D, pharmacological co-targeting of AKT and SGK at a constant inhibitors ratio, showing synergistic interaction between the two compounds. E, long-term treatment of T4888M cells with the indicated inhibitors, showing progressive resistance to PI3K inhibition, and complete growth suppression with combined AKT and SGK inhibition.